Drug Interaction Report

Consumer information for this interaction is not currently available.

MONITOR: Coadministration with inhibitors of CYP450 1A2 and/or 3A4 may increase the plasma concentrations of tasimelteon, which is primarily metabolized by these isoenzymes. When tasimelteon was administered after 6 days of treatment with the potent CYP450 1A2 inhibitor fluvoxamine 50 mg/day, tasimelteon peak plasma concentration (Cmax) and systemic exposure (AUC) increased by 2- and 7-fold, respectively, compared to tasimelteon administered alone. When administered after 5 days of treatment with the potent CYP450 3A4 inhibitor ketoconazole 400 mg/day, tasimelteon AUC increased by approximately 50%.

MANAGEMENT: Caution is advised if tasimelteon is prescribed in combination with inhibitors of CYP450 1A2 and/or 3A4. Patients should be monitored for excessive sedation and other side effects.

Food can delay the absorption of tasimelteon, which may increase the amount of time it takes for the medication to work. You should take tasimelteon without food at the same time each night before going to bed. If you are a smoker, there is a possibility that tasimelteon may not work as well for you due to reduced blood levels of the medication in smokers compared to nonsmokers. You should avoid or limit the use of alcohol while being treated with tasimelteon. It can increase some of the side effects including dizziness, drowsiness, and difficulty concentrating. Some people may also experience impairment in thinking and judgment. Talk to your doctor or pharmacist if you have any questions or concerns.

Information for this minor interaction is available on the professional version.